# OnCo record omacetaxine (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/omacetaxine/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "omacetaxine" ;
  schema:name "Omacetaxine mepesuccinate"@en ;
  schema:alternateName "Homoharringtonine"@en, "Synribo" ;
  schema:description "Omacetaxine (Synribo) is a twice-daily injection under the skin for chronic myeloid leukaemia that has stopped responding to at least two tyrosine kinase inhibitor pills."@en ;
  schema:url <https://onco.cc/drugs/omacetaxine/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Omacetaxine_mepesuccinate> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=omacetaxine>, <https://www.cancer.gov/about-cancer/treatment/drugs/omacetaxinemepesuccinate> ;
  onco:status "approved" ;
  onco:tag "nci-list" ;
  onco:modality "Protein synthesis inhibitor (cephalotaxine ester)" ;
  onco:approval "US 2012: Chronic or accelerated phase CML resistant or intolerant to two or more TKIs (accelerated; full approval 2014)" ;
  onco:acceleratedApproval "US 2012-10-26: Adults with chronic or accelerated phase chronic myeloid leukemia with resistance or intolerance to 2 or more TKIs" ;
  onco:acceleratedApprovalConfirmed "US 2014-02-10: Adults with chronic or accelerated phase chronic myeloid leukemia with resistance or intolerance to 2 or more TKIs" ;
  onco:cancers <https://onco.cc/cancers/cml/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/> ;
  onco:companies <https://onco.cc/companies/teva/> .